Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028
The precision medicine market is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the precision medicine market include growing initiatives related to genomic research, and increasing number of regulatory approvals for personalized therapeutics. Moreover, rising demand for cell and gene therapies is an opportunity area for this market.
The precision medicine market has been segmented based on type, indication, end user and region.
“By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market”
Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.
“By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market”
Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precison medicine regime.
“North America: the largest share of the precision medicine market”
North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.
“Europe: The fastest-growing region in the precision medicine market.”
The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
The precision medicine market has been segmented based on type, indication, end user and region.
“By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market”
Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.
“By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market”
Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precison medicine regime.
“North America: the largest share of the precision medicine market”
North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.
“Europe: The fastest-growing region in the precision medicine market.”
The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
- By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 2.5% & Africa- 2.5%
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- Bristol Myers Squibb (US)
- AstraZeneca (UK)
- Gilead Sciences, Inc. (US)
- AbbVie Inc. (US)
- Eli Lilly and Company (US)
- GlaxoSmithKline plc (UK)
- Sanofi (France)
- Johnson & Johnson (US)
- Merck KGaA (Germany)
- Amgen, Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Regeneron Pharmaceuticals, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- bluebird bio, Inc. (US)
- Immunocore Holdings Plc (UK)
- Blueprint Medicines Corporation (US)
- Vertex Pharmaceuticals Incorporated (US)
- Horizon Therapeutics Plc (Ireland)
- Alnylam Pharmaceuticals, Inc. (US)
- Rigel Pharmaceuticals, Inc. (US)
- Taiho Pharmaceutical Co., Ltd. (Japan)
- Seagen Inc. (US)
This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
- Analysis of key drivers (growth in genomic research, genetic testing and companion diagnostics), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with precision medicines adoption) influencing the growth of the precision medicine market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the precision medicine market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the precision medicine market across varied regions.
- Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the precision medicine market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others in the precision medicine market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 8 PRECISION MEDICINE MARKET: CAGR PROJECTIONS
FIGURE 9 PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028
FIGURE 13 PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET
4 PREMIUM INSIGHTS
4.1 PRECISION MEDICINE MARKET OVERVIEW
FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET
4.2 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY
FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022)
4.3 PRECISION MEDICINE MARKET, BY INDICATION
FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on genomic research
TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE
5.2.1.2 Growth in genetic testing and companion diagnostics
5.2.1.3 Increasing regulatory approvals for personalized therapeutics
5.2.2 RESTRAINTS
5.2.2.1 High costs of therapeutic development
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell and gene therapies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with adoption of precision medicine
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 20 PRECISION MEDICINE MARKET: VALUE CHAIN
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 MANUFACTURING
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES
5.6 ECOSYSTEM ANALYSIS
FIGURE 21 PRECISION MEDICINE MARKET: ECOSYSTEM MAP
5.7 PATENT ANALYSIS
FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012–JULY 2023)
TABLE 4 PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS
5.8 PIPELINE ANALYSIS
TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE
5.9 SUPPLY CHAIN ANALYSIS
5.9.1 PROMINENT COMPANIES
5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.9.3 END USERS
5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
5.9.5 REGULATORY BODIES
FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
TABLE 6 PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM
5.10 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 KEY CONFERENCES AND EVENTS
TABLE 12 PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS
5.14.2 BUYING CRITERIA FOR PRECISION MEDICINE MARKET
FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS
6 PRECISION MEDICINE MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 13 PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 INHIBITOR DRUGS
6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET
TABLE 14 APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022)
TABLE 15 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 MONOCLONAL ANTIBODIES
6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
TABLE 19 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CELL AND GENE THERAPY
6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET
TABLE 23 PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS
6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH
TABLE 27 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 OTHER THERAPEUTIC PRODUCTS
TABLE 31 PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
7 PRECISION MEDICINE MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 35 PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET
TABLE 36 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RARE DISEASES
7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
TABLE 40 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 INFECTIOUS DISEASES
7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET
TABLE 44 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 HEMATOLOGICAL DISORDERS
7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH
TABLE 48 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OTHER INDICATIONS
TABLE 52 PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 PRECISION MEDICINE MARKET, BY END USER
8.1 INTRODUCTION
TABLE 56 PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 HOSPITALS AND CLINICS
8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET
TABLE 57 PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 HOME CARE SETTINGS
8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH
TABLE 61 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
9 PRECISION MEDICINE MARKET, BY REGION
9.1 INTRODUCTION
TABLE 65 PRECISION MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.1 US
9.2.1.1 Rising regulatory approvals for therapeutic products to drive market
TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA
TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising incidence of cancer to drive market
TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT
TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Rising R&D initiatives for therapeutics to drive market
TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.2 UK
9.3.2.1 Rising incidence of hematologic cancers to drive market
TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Increasing initiatives in genomic research to drive market
TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Growing awareness initiatives for personalized treatment to propel market
TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth
TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 97 REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 99 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 103 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 CHINA
9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market
TABLE 104 CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 106 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Availability of reimbursements for medical procedures to support market growth
TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 109 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising burden of chronic diseases to drive market
TABLE 110 INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 112 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Rising R&D projects for genomic sequencing to propel market
TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 115 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.6 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.2 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST
9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 122 MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 124 MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.7 AFRICA
9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 127 AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
10.2 MARKET SHARE ANALYSIS
FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 128 PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.3 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020?2022)
10.4 COMPANY EVALUATION MATRIX
FIGURE 30 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022)
10.4.1 STARS
10.4.2 PERVASIVE PLAYERS
10.4.3 EMERGING LEADERS
10.4.4 PARTICIPANTS
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 DYNAMIC COMPANIES
10.5.4 RESPONSIVE COMPANIES
10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS
10.6.1 PRODUCT FOOTPRINT OF COMPANIES
TABLE 129 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS
10.6.2 REGIONAL FOOTPRINT OF COMPANIES
TABLE 130 PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS
10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 131 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 132 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.8 COMPETITIVE SCENARIO AND TRENDS
10.8.1 PRODUCT APPROVALS
TABLE 133 PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020?JUNE 2023)
10.8.2 DEALS
TABLE 134 PRECISION MEDICINE MARKET: DEALS (JANUARY 2020?JUNE 2023)
10.8.3 OTHER DEVELOPMENTS
TABLE 135 PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020?JULY 2023)
11 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS
11.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS
11.1.2 BRISTOL MYERS SQUIBB
TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW
FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)
TABLE 139 BRISTOL MYERS SQUIBB: DEALS
TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS
11.1.3 NOVARTIS AG
TABLE 141 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
TABLE 142 NOVARTIS AG: DEALS
TABLE 143 NOVARTIS AG: PRODUCT APPROVALS
11.1.4 GILEAD SCIENCES, INC.
TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
TABLE 145 GILEAD SCIENCES, INC.: DEALS
TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
11.1.5 ASTRAZENECA
TABLE 147 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022)
TABLE 148 ASTRAZENECA: DEALS
TABLE 149 ASTRAZENECA: PRODUCT APPROVALS
11.1.6 ABBVIE INC.
TABLE 150 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022)
TABLE 151 ABBVIE INC.: DEALS
11.1.7 ELI LILLY AND COMPANY
TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
TABLE 153 ELI LILLY AND COMPANY: DEALS
TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
11.1.8 SAREPTA THERAPEUTICS, INC.
TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS
TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
11.1.9 PFIZER INC.
TABLE 159 PFIZER INC.: COMPANY OVERVIEW
FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022)
TABLE 160 PFIZER INC.: DEALS
TABLE 161 PFIZER INC.: PRODUCT APPROVALS
TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS
11.1.10 GLAXOSMITHKLINE PLC
TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
TABLE 164 GLAXOSMITHKLINE PLC: DEALS
TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
11.1.11 SANOFI
TABLE 166 SANOFI: COMPANY OVERVIEW
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022)
TABLE 167 SANOFI: DEALS
TABLE 168 SANOFI: PRODUCT APPROVALS
11.1.12 JOHNSON & JOHNSON
TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS
11.1.13 BLUEBIRD BIO, INC.
TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES
TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS
11.1.14 MERCK KGAA
TABLE 174 MERCK KGAA: COMPANY OVERVIEW
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 175 MERCK KGAA: PRODUCT APPROVALS
11.1.15 AMGEN, INC.
TABLE 176 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022)
TABLE 177 AMGEN, INC.: DEALS
TABLE 178 AMGEN, INC.: PRODUCT APPROVALS
11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
11.1.17 REGENERON PHARMACEUTICALS, INC.
TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS
TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS
11.1.18 IMMUNOCORE LTD.
TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW
FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)
TABLE 185 IMMUNOCORE LTD.: DEALS
TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS
11.1.19 BLUEPRINT MEDICINES CORPORATION
TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW
FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)
TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS
TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS
11.2 OTHER PLAYERS
11.2.1 VERTEX PHARMACEUTICALS INCORPORATED
11.2.2 MIRATI THERAPEUTICS, INC
11.2.3 ARGENX SE
11.2.4 HORIZON THERAPEUTICS PLC
11.2.5 BRIDGEBIO PHARMA, INC.
11.2.6 TREVENA, INC.
11.2.7 INCYTE CORPORATION
11.2.8 ALNYLAM PHARMACEUTICALS, INC.
11.2.9 RIGEL PHARMACEUTICALS, INC.
11.2.10 TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.)
11.2.11 AGIOS PHARMACEUTICALS, INC.
11.2.12 SEAGEN, INC.
11.2.13 RHYTHM PHARMACEUTICALS, INC.
11.2.14 MACROGENICS, INC.
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 8 PRECISION MEDICINE MARKET: CAGR PROJECTIONS
FIGURE 9 PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028
FIGURE 13 PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET
4 PREMIUM INSIGHTS
4.1 PRECISION MEDICINE MARKET OVERVIEW
FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET
4.2 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY
FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022)
4.3 PRECISION MEDICINE MARKET, BY INDICATION
FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on genomic research
TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE
5.2.1.2 Growth in genetic testing and companion diagnostics
5.2.1.3 Increasing regulatory approvals for personalized therapeutics
5.2.2 RESTRAINTS
5.2.2.1 High costs of therapeutic development
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell and gene therapies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with adoption of precision medicine
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 20 PRECISION MEDICINE MARKET: VALUE CHAIN
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 MANUFACTURING
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES
5.6 ECOSYSTEM ANALYSIS
FIGURE 21 PRECISION MEDICINE MARKET: ECOSYSTEM MAP
5.7 PATENT ANALYSIS
FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012–JULY 2023)
TABLE 4 PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS
5.8 PIPELINE ANALYSIS
TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE
5.9 SUPPLY CHAIN ANALYSIS
5.9.1 PROMINENT COMPANIES
5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.9.3 END USERS
5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
5.9.5 REGULATORY BODIES
FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
TABLE 6 PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM
5.10 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 KEY CONFERENCES AND EVENTS
TABLE 12 PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS
5.14.2 BUYING CRITERIA FOR PRECISION MEDICINE MARKET
FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS
6 PRECISION MEDICINE MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 13 PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 INHIBITOR DRUGS
6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET
TABLE 14 APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022)
TABLE 15 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 MONOCLONAL ANTIBODIES
6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
TABLE 19 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 CELL AND GENE THERAPY
6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET
TABLE 23 PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS
6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH
TABLE 27 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 OTHER THERAPEUTIC PRODUCTS
TABLE 31 PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
7 PRECISION MEDICINE MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 35 PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET
TABLE 36 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RARE DISEASES
7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
TABLE 40 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 INFECTIOUS DISEASES
7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET
TABLE 44 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 HEMATOLOGICAL DISORDERS
7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH
TABLE 48 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OTHER INDICATIONS
TABLE 52 PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 PRECISION MEDICINE MARKET, BY END USER
8.1 INTRODUCTION
TABLE 56 PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 HOSPITALS AND CLINICS
8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET
TABLE 57 PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 HOME CARE SETTINGS
8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH
TABLE 61 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
9 PRECISION MEDICINE MARKET, BY REGION
9.1 INTRODUCTION
TABLE 65 PRECISION MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.1 US
9.2.1.1 Rising regulatory approvals for therapeutic products to drive market
TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA
TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising incidence of cancer to drive market
TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT
TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Rising R&D initiatives for therapeutics to drive market
TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.2 UK
9.3.2.1 Rising incidence of hematologic cancers to drive market
TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Increasing initiatives in genomic research to drive market
TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Growing awareness initiatives for personalized treatment to propel market
TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth
TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 97 REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 99 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 103 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 CHINA
9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market
TABLE 104 CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 106 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Availability of reimbursements for medical procedures to support market growth
TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 109 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising burden of chronic diseases to drive market
TABLE 110 INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 112 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Rising R&D projects for genomic sequencing to propel market
TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 115 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.6 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.2 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST
9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 122 MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 124 MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.7 AFRICA
9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 127 AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
10.2 MARKET SHARE ANALYSIS
FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 128 PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.3 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020?2022)
10.4 COMPANY EVALUATION MATRIX
FIGURE 30 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022)
10.4.1 STARS
10.4.2 PERVASIVE PLAYERS
10.4.3 EMERGING LEADERS
10.4.4 PARTICIPANTS
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 DYNAMIC COMPANIES
10.5.4 RESPONSIVE COMPANIES
10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS
10.6.1 PRODUCT FOOTPRINT OF COMPANIES
TABLE 129 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS
10.6.2 REGIONAL FOOTPRINT OF COMPANIES
TABLE 130 PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS
10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 131 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 132 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.8 COMPETITIVE SCENARIO AND TRENDS
10.8.1 PRODUCT APPROVALS
TABLE 133 PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020?JUNE 2023)
10.8.2 DEALS
TABLE 134 PRECISION MEDICINE MARKET: DEALS (JANUARY 2020?JUNE 2023)
10.8.3 OTHER DEVELOPMENTS
TABLE 135 PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020?JULY 2023)
11 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS
11.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS
11.1.2 BRISTOL MYERS SQUIBB
TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW
FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)
TABLE 139 BRISTOL MYERS SQUIBB: DEALS
TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS
11.1.3 NOVARTIS AG
TABLE 141 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
TABLE 142 NOVARTIS AG: DEALS
TABLE 143 NOVARTIS AG: PRODUCT APPROVALS
11.1.4 GILEAD SCIENCES, INC.
TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
TABLE 145 GILEAD SCIENCES, INC.: DEALS
TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
11.1.5 ASTRAZENECA
TABLE 147 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022)
TABLE 148 ASTRAZENECA: DEALS
TABLE 149 ASTRAZENECA: PRODUCT APPROVALS
11.1.6 ABBVIE INC.
TABLE 150 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022)
TABLE 151 ABBVIE INC.: DEALS
11.1.7 ELI LILLY AND COMPANY
TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
TABLE 153 ELI LILLY AND COMPANY: DEALS
TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
11.1.8 SAREPTA THERAPEUTICS, INC.
TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS
TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
11.1.9 PFIZER INC.
TABLE 159 PFIZER INC.: COMPANY OVERVIEW
FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022)
TABLE 160 PFIZER INC.: DEALS
TABLE 161 PFIZER INC.: PRODUCT APPROVALS
TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS
11.1.10 GLAXOSMITHKLINE PLC
TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
TABLE 164 GLAXOSMITHKLINE PLC: DEALS
TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
11.1.11 SANOFI
TABLE 166 SANOFI: COMPANY OVERVIEW
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022)
TABLE 167 SANOFI: DEALS
TABLE 168 SANOFI: PRODUCT APPROVALS
11.1.12 JOHNSON & JOHNSON
TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS
11.1.13 BLUEBIRD BIO, INC.
TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES
TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS
11.1.14 MERCK KGAA
TABLE 174 MERCK KGAA: COMPANY OVERVIEW
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 175 MERCK KGAA: PRODUCT APPROVALS
11.1.15 AMGEN, INC.
TABLE 176 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022)
TABLE 177 AMGEN, INC.: DEALS
TABLE 178 AMGEN, INC.: PRODUCT APPROVALS
11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
11.1.17 REGENERON PHARMACEUTICALS, INC.
TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS
TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS
11.1.18 IMMUNOCORE LTD.
TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW
FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)
TABLE 185 IMMUNOCORE LTD.: DEALS
TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS
11.1.19 BLUEPRINT MEDICINES CORPORATION
TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW
FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)
TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS
TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS
11.2 OTHER PLAYERS
11.2.1 VERTEX PHARMACEUTICALS INCORPORATED
11.2.2 MIRATI THERAPEUTICS, INC
11.2.3 ARGENX SE
11.2.4 HORIZON THERAPEUTICS PLC
11.2.5 BRIDGEBIO PHARMA, INC.
11.2.6 TREVENA, INC.
11.2.7 INCYTE CORPORATION
11.2.8 ALNYLAM PHARMACEUTICALS, INC.
11.2.9 RIGEL PHARMACEUTICALS, INC.
11.2.10 TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.)
11.2.11 AGIOS PHARMACEUTICALS, INC.
11.2.12 SEAGEN, INC.
11.2.13 RHYTHM PHARMACEUTICALS, INC.
11.2.14 MACROGENICS, INC.
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
